Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress
Shattuck Labs (NASDAQ: STTK) has announced an upcoming poster presentation at the 2025 Crohn's and Colitis Congress in San Francisco, California, scheduled for February 6-8, 2025. The presentation will focus on SL-325, a DR3-targeted, antagonistic antibody developed for the treatment of IBD.
The poster will be presented by Dr. Suresh de Silva, Shattuck's Co-Chief Scientific Officer, on Friday, February 7, 2025, from 5:00 PM to 6:30 PM PST at the Congress Exhibit Hall in The Moscone Center. The presentation materials will be made available on the company's website in the Events and Presentations section after the event.
Shattuck Labs (NASDAQ: STTK) ha annunciato una prossima presentazione di poster al Congress 2025 su Crohn e Colite a San Francisco, California, programmata per il 6-8 febbraio 2025. La presentazione si concentrerà su SL-325, un anticorpo antagonista mirato a DR3 sviluppato per il trattamento della IBD.
Il poster sarà presentato dal Dr. Suresh de Silva, Co-Chief Scientific Officer di Shattuck, venerdì 7 febbraio 2025, dalle 17:00 alle 18:30 PST presso l'Congress Exhibit Hall nel Moscone Center. I materiali della presentazione saranno resi disponibili sul sito web dell'azienda nella sezione Eventi e Presentazioni dopo l'evento.
Shattuck Labs (NASDAQ: STTK) ha anunciado una próxima presentación de póster en el Congreso 2025 de Crohn y Colitis en San Francisco, California, programada para el 6-8 de febrero de 2025. La presentación se centrará en SL-325, un anticuerpo antagonista dirigido a DR3 desarrollado para el tratamiento de IBD.
El póster será presentado por el Dr. Suresh de Silva, Co-Chief Scientific Officer de Shattuck, el viernes 7 de febrero de 2025, de 5:00 PM a 6:30 PM PST en el Congreso Exhibit Hall en el Moscone Center. Los materiales de la presentación estarán disponibles en el sitio web de la empresa en la sección de Eventos y Presentaciones después del evento.
Shattuck Labs (NASDAQ: STTK)가 2025년 2월 6일부터 8일까지 캘리포니아 샌프란시스코에서 열릴 2025 크론병 및 대장염 컨그레스에서 포스터 발표를 예정하고 있다고 발표했습니다. 발표는 IBD 치료를 위해 개발된 DR3 표적의 길항 항체인 SL-325에 초점을 맞출 것입니다.
해당 포스터는 Shattuck의 Co-Chief Scientific Officer인 Dr. Suresh de Silva에 의해 2025년 2월 7일 금요일 오후 5시부터 6시 30분까지 PST로 Moscone Center의 Congress Exhibit Hall에서 발표됩니다. 발표 자료는 행사 후 회사 웹사이트의 이벤트 및 발표 섹션에서 확인할 수 있습니다.
Shattuck Labs (NASDAQ: STTK) a annoncé une prochaine présentation d'affiche lors du Congrès 2025 sur la maladie de Crohn et la colite à San Francisco, Californie, prévue du 6 au 8 février 2025. La présentation sera axée sur SL-325, un anticorps antagoniste ciblant DR3 développé pour le traitement de la MII.
L'affiche sera présentée par le Dr Suresh de Silva, Co-Chief Scientific Officer de Shattuck, le vendredi 7 février 2025, de 17h00 à 18h30 PST au Congress Exhibit Hall au Moscone Center. Les documents de présentation seront disponibles sur le site web de l'entreprise dans la section Événements et Présentations après l'événement.
Shattuck Labs (NASDAQ: STTK) hat eine bevorstehende Posterpräsentation beim 2025 Crohn's und Colitis Kongress in San Francisco, Kalifornien, angekündigt, die für den 6.-8. Februar 2025 geplant ist. Die Präsentation wird sich auf SL-325, einen antagonistischen Antikörper, der auf DR3 abzielt und zur Behandlung von IBD entwickelt wurde, konzentrieren.
Das Poster wird von Dr. Suresh de Silva, Co-Chief Scientific Officer von Shattuck, am Freitag, den 7. Februar 2025, von 17:00 bis 18:30 PST im Congress Exhibit Hall im Moscone Center präsentiert. Die Präsentationsunterlagen werden nach der Veranstaltung auf der Website des Unternehmens im Bereich Veranstaltungen und Präsentationen verfügbar gemacht.
- None.
- None.
AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced an upcoming poster presentation at the 2025 Crohn’s and Colitis Congress being held in San Francisco, California from February 6–8, 2025.
Presentation Details
Format: Poster presentation
Title: Development and Characterization of SL-325, a DR3-Targeted, Antagonistic Antibody for the Treatment of IBD
Presenter: Suresh de Silva, Ph.D., Shattuck’s Co-Chief Scientific Officer
Date/Time: Friday, February 7, 2025; 5:00 PM – 6:30 PM PST
Location: Congress Exhibit Hall, The Moscone Center, Level 1; San Francisco, CA
The poster will be available on the Events and Presentations section of the Company’s website following the presentation.
About Shattuck Labs, Inc.
Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treatments for autoimmune/inflammatory diseases. The Company is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory autoimmune diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor agonist and antagonist therapeutics come together in its lead program, SL-325, a first-in-class DR3 antagonist antibody designed to achieve complete and durable blockade of the clinically validated TL1A/DR3 pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor & Media Contact:
Conor Richardson
Vice President of Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
FAQ
What will Shattuck Labs (STTK) present at the 2025 Crohn's and Colitis Congress?
When and where is Shattuck Labs (STTK) presenting at the 2025 Crohn's and Colitis Congress?
Who will present Shattuck Labs' (STTK) research at the 2025 Crohn's and Colitis Congress?
Where can investors find Shattuck Labs' (STTK) 2025 Crohn's and Colitis Congress presentation materials?
